Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Roderick Docking is a leading figure in clinical genomics and precision oncology, whose work has significantly advanced the detection of hereditary cancer syndromes. His most impactful contribution is the development and clinical validation of a second-generation sequencing assay for hereditary BRCA1 and BRCA2 mutations, a landmark study that has garnered 42 citations and established a gold-standard diagnostic approach for identifying high-risk individuals. This work directly translates genomic technology into actionable clinical tools, enabling earlier intervention and personalized treatment strategies for breast and ovarian cancers. Dr. Docking is also recognized for his innovative contributions to laboratory quality control, notably through his development of unique sequence controls for sample tracking, a method that enhances the accuracy and integrity of high-throughput sequencing workflows. His research bridges the gap between cutting-edge genomics and routine clinical practice, ensuring that complex sequencing data are both reliable and interpretable for patient care. Through these achievements, Dr. Docking has cemented his reputation as a vital contributor to the infrastructure of modern molecular diagnostics, empowering clinicians and researchers alike to harness the full potential of genomic medicine.